FDA clears Thoratec's Vectra Access Graft:
This article was originally published in Clinica
Thoratec Laboratories has received 510(k) marketing clearance from the US FDA for its Vectra Vascular Access Graft. The device incorporates the Pleasanton, California-based company's biomaterial, Thoralon, and is designed to provide access to the bloodstream in end-stage renal disease patients undergoing haemodialysis. It has been available in Japan, Australia and Canada for several years, and in Europe since last year.
You may also be interested in...
Top 100 Review: The Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19
2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.
Hikma and Sesen Bio have struck a deal that will see Hikma distribute the Vicineum brand in the MENA region.
By establishing a dedicated consumer healthcare subsidiary, Norgine is hoping it can grow its $200m-plus Movicol laxative brand and take advantage of M&A opportunities in the OTC market.